ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
April 19 2017 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced it will report
financial results for the first quarter 2017 before the market
opens on Wednesday, May 3, 2017. The Company will hold a conference
call and webcast on the same day at 9:00 a.m. ET to discuss these
results and provide a general business update.
The live webcast can be accessed in the “Investors and Media”
section of our website, www.arqule.com, under “Events &
Presentations.” You may also listen to the call by dialing (877)
868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call
and can be accessed in the “Investors & Media” section of our
website, www.arqule.com, under “Events and Presentations.”
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s proprietary pipeline includes: ARQ
087, a multi-kinase inhibitor designed to preferentially inhibit
the fibroblast growth factor receptor (FGFR) family, in phase 2 for
iCCA and in phase 1b for multiple oncology indications; ARQ 092, a
selective inhibitor of the AKT serine/threonine kinase, in phase 1
for multiple oncology indications as well as ultra-rare Proteus
syndrome, in partnership with the National Institutes of Health
(NIH); ARQ 751, a next generation AKT inhibitor, in phase 1 for
patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone
analog being evaluated as a promoter of NQO1-mediated programmed
cancer cell necrosis, in phase 1/2 in multiple oncology indications
in partnership with the University of Texas Southwestern Medical
Center. In addition, we have advanced ARQ 531, an investigational,
orally bioavailable, potent and reversible inhibitor of both wild
type and C481S-mutant BTK, through toxicology testing and plan to
initiate a phase 1 trial by the third quarter of 2017. ArQule’s
current discovery efforts are focused on the identification and
development of novel kinase inhibitors, leveraging the Company’s
proprietary library of compounds. You can follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170419005079/en/
ArQuleDawn Schottlandt, 781-994-0300Sr. Director, Investor
Relations/Corp. Communicationswww.arqule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2023 to Apr 2024